Generic Medicine Info
Indications and Dosage
Chronic psychosis
Adult: Initially, 0.5 mg daily. Adjust dosage upward or downward according to response. Dosage range: 0.1-1 mg daily.

Adult: Initially, up to 0.5 mg daily for 1-2 wk, subsequently reduced to the lowest dose necessary to maintain response. Maintenance: 0.1-0.25 mg daily. Max: 0.5 mg daily.
Should be taken with food.
Active peptic ulcer or ulcerative colitis; history of mental depression; phaeochromocytoma, Parkinson’s disease. Patient receiving electroconvulsive therapy (ECT).
Special Precautions
Patient w/ MI, cardiac arrhythmias, gallstones, epilepsy, allergic conditions (e.g. bronchial asthma). Hypertensive patient w/ renal insufficiency. Pregnancy and lactation.
Adverse Reactions
Nasal congestion, headache, CNS symptoms including depression, drowsiness, dizziness, lethargy, nightmares; GI disturbance including diarrhoea, abdominal cramps, increased gastric acid secretion; flushing, bradycardia, extrapyramidal effects, hypotension, convulsion, breast engorgement, galactorrhoea, gynaecomastia, increased prolactin concentrations, decreased libido, impotence, Na retention, oedema, decreased or increased appetite, wt gain, miosis, dry mouth, sialorrhoea, dysuria, rashes, pruritus, thrombocytopenic purpura.
Monitoring Parameters
Asses/monitor BP and cardiac status prior to starting therapy, during first doses, when changing dose and regularly, thereafter.
Symptoms: Impaired consciousness ranging from drowsiness to coma, flushing, conjunctival injection, pupillary constriction, hypotension, hypothermia, central resp depresson, bradycardia, increased salivary and gastric secretion, diarrhoea. Management: Symptomatic and supportive treatment. Administer activated charcoal w/in 1 hr of ingestion. Place patient in supine position w/ feet raised for severe hypotension or give direct-acting sympathomimetics.
Drug Interactions
Enhanced hypotensive effects w/ thiazide diuretics and other antihypertensives. May cause excitation and HTN in patients receiving MAOIs. Risk of cardiac arrhythmias w/ digitalis or quinidine. May enhance the effects of CNS depressants. May inhibit the action of indirect-acting amines (e.g. ephedrine). May prolong the action of direct-acting amines (epinephrine). Decreased antihypertensive effect w/ TCAs.
Description: Reserpine is an antihypertensive drug that causes depletion of norepinephrine, catecholamine and serotonin stores resulting in a reduction in BP, bradycardia and CNS depression. Decrease in cardiac output and peripheral resistance result in hypotensive effect.
Onset: Antihypertensive: 3-6 days.
Duration: 2-6 wk.
Absorption: Absorbed from the GI tract. Bioavailability: 50%.
Distribution: Crosses the placenta and blood-brain barrier and enters breast milk. Plasma protein binding: 96%.
Metabolism: Extensively metabolised in the liver (>90%).
Excretion: Via faeces (approx 60% as unchanged drug) and urine (approx 8% as metabolites). Elimination half-life: Approx 50-100 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Reserpine, CID=5770, (accessed on Jan. 22, 2020)

Store between 20-25˚C. Protect from moisture.
MIMS Class
Other Antihypertensives
ATC Classification
C02AA02 - reserpine ; Belongs to the class of rauwolfia alkaloids, centrally-acting antiadrenergic agents. Used in the treatment of hypertension.
Anon. Reserpine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 23/05/2016.

Buckingham R (ed). Reserpine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 23/05/2016.

Reserpine Tablet (Eon Labs, Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 23/05/2016.

Disclaimer: This information is independently developed by MIMS based on Reserpine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in